UPDATE 2-Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals
May 20, 2020 at 19:27 PM EDT
Gilead Sciences Inc and partner Galapagos NV said on Wednesday only a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a pivotal study testing it in ulcerative colitis patients. Filgotinib is also in advanced stages of testing against multiple types of inflammatory conditions including rheumatoid arthritis, a market dominated by drugs such as AbbVie's Humira.
